MedTrace Logo

LIFE Study: Least Invasive Fast-Track EVAR

NCT02224794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2021-06-08

No results posted yet for this study

Summary

The primary objectives of the LIFE Study are to demonstrate the clinical and cost benefits associated with using the Ovation® Abdominal Stent Graft Platform under the least invasive conditions defined in the Fast-Track EVAR protocol. The key elements of the Fast-Track EVAR protocol include: appropriate patient selection, bilateral percutaneous access, no general anesthesia, no ICU admission post procedure, and next day discharge.

Conditions

  • Abdominal Aortic Aneurysm

Interventions

DEVICE

Ovation® Abdominal Stent Graft Platform

Sponsors & Collaborators

  • TriVascular, Inc.

    lead INDUSTRY

Principal Investigators

  • Zvonimir Krajcer, MD · CHI St. Luke's Health, Texas

  • Venkatesh Ramaiah, MD · Arizona Heart Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02224794 on ClinicalTrials.gov